Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound Clinical Trials Arena Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased